Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.
Wang Y, Deng B.
Cancer Metastasis Rev. 2023 Sep;42(3):629-652. doi: 10.1007/s10555-023-10084-4. Epub 2023 Feb 2.
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis.
Lev S.
Biochem Soc Trans. 2020 Apr 29;48(2):657-665. doi: 10.1042/BST20191055.
Targeted Therapy and Personalized Medicine.
Saeed RF, Awan UA, Saeed S, Mumtaz S, Akhtar N, Aslam S.
Cancer Treat Res. 2023;185:177-205. doi: 10.1007/978-3-031-27156-4_10.
Advances in targeted therapy for malignant lymphoma.
Wang L, Qin W, Huo YJ, Li X, Shi Q, Rasko JEJ, Janin A, Zhao WL.
Signal Transduct Target Ther. 2020 Mar 6;5(1):15. doi: 10.1038/s41392-020-0113-2.
Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review.
Nappi F.
Int J Mol Sci. 2024 Mar 24;25(7):3630. doi: 10.3390/ijms25073630.
PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas.
Mancarella C, Morrione A, Scotlandi K.
Int J Mol Sci. 2023 Nov 15;24(22):16346. doi: 10.3390/ijms242216346.
RNA-Targeted Therapeutics.
Crooke ST, Witztum JL, Bennett CF, Baker BF.
Cell Metab. 2018 Apr 3;27(4):714-739. doi: 10.1016/j.cmet.2018.03.004.
Targeting AKT for cancer therapy.
Shariati M, Meric-Bernstam F.
Expert Opin Investig Drugs. 2019 Nov;28(11):977-988. doi: 10.1080/13543784.2019.1676726. Epub 2019 Oct 12.
Cancer treatment therapies: traditional to modern approaches to combat cancers.
Kaur R, Bhardwaj A, Gupta S.
Mol Biol Rep. 2023 Nov;50(11):9663-9676. doi: 10.1007/s11033-023-08809-3. Epub 2023 Oct 12.
Biomarkers and targeted therapy for cancer stem cells.
Liu Y, Wang H.
Trends Pharmacol Sci. 2024 Jan;45(1):56-66. doi: 10.1016/j.tips.2023.11.006. Epub 2023 Dec 9.
